Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

NCT02390427 is registered in ClinicalTrials.gov with Nancy Lin, MD as lead sponsor.

NCT NCT02390427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02390427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Lead sponsor
Nancy Lin, MD
Phase
Phase 1
Overall status
Completed
Start date
April 20, 2015
Completion date
July 31, 2024
Enrollment
68 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, recurrent breast cancer